- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 3.05 Å
- Oligo State
- homo-dimer
- Ligands
- 2 x NAG- NAG- FUC: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-[alpha-L-fucopyranose-(1-6)]2-acetamido-2-deoxy-beta-D-glucopyranose
- 1 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-3)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 1 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 12 x SO4: SULFATE ION(Non-functional Binders)
SO4.5: 2 residues within 4Å:- Chain A: T.462, A.463
2 PLIP interactions:2 interactions with chain A- Hydrogen bonds: A:A.463, A:E.464
SO4.6: 2 residues within 4Å:- Chain A: Q.409, R.413
4 PLIP interactions:4 interactions with chain A- Hydrogen bonds: A:Q.409
- Water bridges: A:N.529
- Salt bridges: A:R.413, A:R.530
SO4.7: 3 residues within 4Å:- Chain A: R.352, L.356
- Chain B: R.530
2 PLIP interactions:1 interactions with chain B, 1 interactions with chain A- Salt bridges: B:R.530, A:R.352
SO4.8: 3 residues within 4Å:- Chain A: T.500, G.502, A.503
3 PLIP interactions:3 interactions with chain A- Hydrogen bonds: A:T.500, A:G.502, A:A.503
SO4.9: 1 residues within 4Å:- Chain A: H.318
1 PLIP interactions:1 interactions with chain A- Salt bridges: A:H.318
SO4.10: 3 residues within 4Å:- Chain A: G.236, M.237, G.238
2 PLIP interactions:2 interactions with chain A- Hydrogen bonds: A:M.237, A:G.238
SO4.28: 4 residues within 4Å:- Chain B: T.500, A.501, G.502, A.503
4 PLIP interactions:4 interactions with chain B- Hydrogen bonds: B:T.500, B:A.501, B:G.502, B:A.503
SO4.29: 4 residues within 4Å:- Chain A: R.530
- Chain B: R.352, L.356, W.381
2 PLIP interactions:1 interactions with chain A, 1 interactions with chain B- Salt bridges: A:R.530, B:R.352
SO4.30: 1 residues within 4Å:- Chain B: R.474
1 PLIP interactions:1 interactions with chain B- Salt bridges: B:R.474
SO4.31: 3 residues within 4Å:- Chain B: G.236, M.237, G.238
4 PLIP interactions:4 interactions with chain B- Hydrogen bonds: B:M.237, B:G.238
- Water bridges: B:E.239, B:E.239
SO4.32: 3 residues within 4Å:- Chain B: Q.409, R.413, R.530
3 PLIP interactions:3 interactions with chain B- Hydrogen bonds: B:Q.409
- Water bridges: B:N.529
- Salt bridges: B:R.413
SO4.33: 5 residues within 4Å:- Chain B: P.102, P.104, T.105, S.106, T.108
4 PLIP interactions:4 interactions with chain B- Hydrogen bonds: B:T.105, B:T.105, B:S.106
- Salt bridges: B:R.139
- 2 x CVZ: 3-[(~{E})-5-[ethyl-[(2-nitrophenyl)methyl]amino]pent-1-enyl]-1-[5-[ethyl-[(2-nitrophenyl)methyl]amino]pentyl]-6-methyl-pyrimidine-2,4-dione(Non-covalent)
CVZ.11: 18 residues within 4Å:- Chain A: Y.68, G.78, W.82, G.117, Y.120, E.198, S.199, W.282, H.283, S.289, V.290, F.291, F.293, Y.333, F.334, Y.337, W.435, H.443
11 PLIP interactions:11 interactions with chain A- Hydrophobic interactions: A:W.82, A:V.290, A:F.334, A:Y.337, A:Y.337, A:W.435
- Hydrogen bonds: A:Y.120, A:Y.333
- pi-Stacking: A:W.82, A:W.282, A:H.283
CVZ.34: 16 residues within 4Å:- Chain B: G.78, W.82, G.117, Y.120, E.198, S.199, W.282, H.283, P.286, Q.287, E.288, S.289, Y.333, F.334, Y.337, H.443
16 PLIP interactions:16 interactions with chain B- Hydrophobic interactions: B:W.82, B:W.282, B:W.282, B:H.283, B:E.288, B:F.334, B:F.334, B:Y.337, B:Y.337, B:Y.337
- Hydrogen bonds: B:Y.120, B:Y.333
- Water bridges: B:D.70, B:Y.120
- pi-Stacking: B:W.82, B:W.282
- 29 x CL: CHLORIDE ION(Non-functional Binders)
CL.12: 1 residues within 4Å:- Chain A: Q.177
Ligand excluded by PLIPCL.13: 1 residues within 4Å:- Chain A: R.420
Ligand excluded by PLIPCL.14: 1 residues within 4Å:- Chain A: L.437
Ligand excluded by PLIPCL.15: 2 residues within 4Å:- Chain A: R.12, G.54
Ligand excluded by PLIPCL.16: 3 residues within 4Å:- Chain A: T.105, S.106, R.139
Ligand excluded by PLIPCL.17: 1 residues within 4Å:- Chain A: D.368
Ligand excluded by PLIPCL.18: 1 residues within 4Å:- Chain A: R.132
Ligand excluded by PLIPCL.19: 3 residues within 4Å:- Chain A: H.383, E.385, D.386
Ligand excluded by PLIPCL.20: 2 residues within 4Å:- Chain A: H.383, R.389
Ligand excluded by PLIPCL.21: 2 residues within 4Å:- Chain A: R.530, K.534
Ligand excluded by PLIPCL.22: 2 residues within 4Å:- Chain A: F.76, K.344
Ligand excluded by PLIPCL.23: 3 residues within 4Å:- Chain A: N.229, P.308, E.309
Ligand excluded by PLIPCL.24: 3 residues within 4Å:- Chain A: R.161, T.263
- Ligands: NAG-NAG.2
Ligand excluded by PLIPCL.25: 1 residues within 4Å:- Chain A: R.413
Ligand excluded by PLIPCL.26: 2 residues within 4Å:- Chain A: R.517, R.518
Ligand excluded by PLIPCL.27: 3 residues within 4Å:- Chain A: R.521, Q.523, A.524
Ligand excluded by PLIPCL.35: 2 residues within 4Å:- Chain B: P.158, R.241
Ligand excluded by PLIPCL.36: 1 residues within 4Å:- Chain B: R.389
Ligand excluded by PLIPCL.37: 1 residues within 4Å:- Chain B: R.521
Ligand excluded by PLIPCL.38: 2 residues within 4Å:- Chain B: K.19, R.132
Ligand excluded by PLIPCL.39: 1 residues within 4Å:- Chain B: K.49
Ligand excluded by PLIPCL.40: 3 residues within 4Å:- Chain B: H.383, E.385, D.386
Ligand excluded by PLIPCL.41: 1 residues within 4Å:- Chain B: R.389
Ligand excluded by PLIPCL.42: 2 residues within 4Å:- Chain B: R.12, G.54
Ligand excluded by PLIPCL.43: 2 residues within 4Å:- Chain B: R.215, L.320
Ligand excluded by PLIPCL.44: 3 residues within 4Å:- Chain B: R.521, Q.523, A.524
Ligand excluded by PLIPCL.45: 2 residues within 4Å:- Chain B: P.436, L.437
Ligand excluded by PLIPCL.46: 2 residues within 4Å:- Chain B: A.493, Q.495
Ligand excluded by PLIPCL.47: 3 residues within 4Å:- Chain B: G.238, E.239, R.242
Ligand excluded by PLIP- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Zueva, I. et al., New evidence for dual binding site inhibitors of acetylcholinesterase as improved drugs for treatment of Alzheimer's disease. Neuropharmacology (2019)
- Release Date
- 2018-12-12
- Peptides
- Acetylcholinesterase: AB
- SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AB
B
- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 3.05 Å
- Oligo State
- homo-dimer
- Ligands
- 2 x NAG- NAG- FUC: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-[alpha-L-fucopyranose-(1-6)]2-acetamido-2-deoxy-beta-D-glucopyranose
- 1 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-3)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 1 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 12 x SO4: SULFATE ION(Non-functional Binders)
- 2 x CVZ: 3-[(~{E})-5-[ethyl-[(2-nitrophenyl)methyl]amino]pent-1-enyl]-1-[5-[ethyl-[(2-nitrophenyl)methyl]amino]pentyl]-6-methyl-pyrimidine-2,4-dione(Non-covalent)
- 29 x CL: CHLORIDE ION(Non-functional Binders)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Zueva, I. et al., New evidence for dual binding site inhibitors of acetylcholinesterase as improved drugs for treatment of Alzheimer's disease. Neuropharmacology (2019)
- Release Date
- 2018-12-12
- Peptides
- Acetylcholinesterase: AB
- SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AB
B